Patents Assigned to Genentech
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11638756
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 2, 2023
    Assignees: Genentech, Inc., Hoffman-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11639395
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: May 2, 2023
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • BIOMARKERS FOR PREDICTING RESPONSE TO IL-6 ANTAGONIST IN COVID-19 PNEUMONIA
    Publication number: 20230125415
    Abstract: A method of treating pneumonia in a patient is disclosed comprising administering an effective amount of an IL-6 antagonist to a patient identified as having elevated ferritin level. Also disclosed is a method of achieving an improved clinical response in a patient with pneumonia comprising: a. measuring ferritin level in the patient, and b. administering an effective amount of an IL-6 antagonist to the patient identified as having an elevated ferritin level. The improved clinical response achieved includes: no death by Day 28, not mechanically ventilated by Day 28 (wherein the patient was not mechanically ventilated at baseline), better ordinal score at Day 28, and/or reduced time to hospital discharge within 28 days, compared to the clinical response in a patient with pneumonia and ferritin level that is not elevated.
    Type: Application
    Filed: March 19, 2021
    Publication date: April 27, 2023
    Applicant: Genentech, Inc.
    Inventors: Min Bao, Fang Cai, Jennifer Tom, Larry Wilse Tsai
  • Cysteine Engineered Antibodies and Conjugates
    Publication number: 20230130874
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
    Type: Application
    Filed: May 13, 2022
    Publication date: April 27, 2023
    Applicant: Genentech, Inc.
    Inventors: Sunil Bhakta, Hans Erickson, Jagath R. Junutula, Katherine Kozak, Rachana Ohri, Thomas Harden Pillow
  • Randomized configuration targeted integration of nucleic acids
    Patent number: 11634836
    Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: April 25, 2023
    Assignee: Genentech, Inc.
    Inventors: Shahram Misaghi, Bradley R. Snedecor
  • Pyridine lactam compounds and methods of use thereof
    Patent number: 11634436
    Abstract: The invention provides compounds having the general formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R7a, R7b, X, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of use thereof.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: April 25, 2023
    Assignee: Genentech, Inc.
    Inventor: Snahel Patel
  • Versatile syringe platform
    Patent number: 11633545
    Abstract: Apparatus and methods for medicament delivery. The apparatus may include, and the methods may involve, a delivery device for delivering a target amount of the medicament from a distal end of the device. The device may include a rod for moving a plunger that discharges the medicament from the distal end. The device may avoid or reduce deformation of the plunger during the discharge. The plunger motion may be stopped by detent that interacts with the rod. The apparatus and the methods may provide an operator indication of progress of stages of operation. The device may feature triggers corresponding to stages of medicament displacement from the device, such as pre-delivery stages, including priming.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 25, 2023
    Assignee: Genentech, Inc.
    Inventors: Lionel Vedrine, Steven N. Roe, Mukund Patel
  • PREDICTION OF PEPTIDE CLEAVAGE IN POLYPEPTIDES THROUGH PHYSICS-BASED SIMULATIONS
    Publication number: 20230120018
    Abstract: The present disclosure relates to polypeptide degradation, and in particular to techniques for predicting the likelihood that a peptide bond for a given polypeptide molecule is susceptible to a cleavage reaction.
    Type: Application
    Filed: November 22, 2022
    Publication date: April 20, 2023
    Applicant: Genentech, Inc.
    Inventors: Karthikan Rajagopal, Nisana Marie Andersen, Saeed Izadi, Robert Franklin Kelley, JR.
  • HIGH DOSE TREATMENTS FOR ALZHEIMER'S DISEASE
    Publication number: 20230123110
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
    Type: Application
    Filed: June 1, 2022
    Publication date: April 20, 2023
    Applicant: GENENTECH, INC.
    Inventors: Jillian Smith, Janice Smith, Geoff Kerchner
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20230121700
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: August 2, 2022
    Publication date: April 20, 2023
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander TERRETT, Huifen CHEN, Lea CONSTANTINEAU-FORGET, Robin Larouche-Gauthier, Luce LÉPISSIER, Francis BEAUMIER, Martin DÉRY, Chantal GRAND-MAÎTRE, Claudio STURINO, Matthew VOLGRAF, Elisia VILLEMURE
  • THERAPEUTIC COMPOUNDS AND METHODS
    Publication number: 20230119740
    Abstract: The invention provides a compound of formula (I): or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.
    Type: Application
    Filed: July 12, 2022
    Publication date: April 20, 2023
    Applicant: GENENTECH, INC.
    Inventors: Samantha Alyson GREEN, Jessica Marie GRANDNER, Steven Thomas STABEN, Neri AMARA, Vishva M. DIXIT, Elisia VILLEMURE
  • THERAPEUTIC COMPOUNDS
    Publication number: 20230112485
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Application
    Filed: August 8, 2022
    Publication date: April 13, 2023
    Applicant: Genentech, Inc.
    Inventors: Elisia VILLEMURE, Joachim RUDOLPH, Mingshuo ZENG
  • METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230099756
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody, chemotherapy and a corticosteroid.
    Type: Application
    Filed: August 5, 2022
    Publication date: March 30, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jamie Harue HIRATA, Calvin Ka Yin Lee, Huan Jin, Lijia Wang, Jiaheng Qiu, Qingxiang Yan
  • 8-aminoisoquinoline compounds and uses thereof
    Patent number: 11612606
    Abstract: 3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: March 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
  • METHODS OF TREATING PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE
    Publication number: 20230091561
    Abstract: Provided herein are methods of treating Primary Progressive Multiple Sclerosis (PPMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: March 23, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
  • COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
    Publication number: 20230088701
    Abstract: Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+/HER2?) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
    Type: Application
    Filed: June 3, 2022
    Publication date: March 23, 2023
    Applicant: Genentech, Inc.
    Inventors: Jennifer O'Hara Lauchle, Michael Joseph Mamounas, Jennifer Lee Schutzman, Lori Sickels Friedman, Jian Huang
  • METHODS FOR MAKING EXTRACELLULAR VESICLES AND USES THEREOF
    Publication number: 20230090177
    Abstract: The present disclosure relates to improved methods and compositions for making extracellular vesicles (EVs). The present disclosure also relates to novel EV-based ELISA assays and kits for performing such assays, as well as methods of producing antibodies to particular antigens using EVs comprising membrane-bound antigen.
    Type: Application
    Filed: November 28, 2022
    Publication date: March 23, 2023
    Applicant: GENENTECH, INC.
    Inventors: James Thomas Koerber, Yonglian Sun
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20230092354
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: August 22, 2022
    Publication date: March 23, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • Bicyclic amide compounds and methods of use thereof
    Patent number: 11607396
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: March 21, 2023
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
  • LACTAMS AS CBL-B INHIBITORS
    Publication number: 20230079990
    Abstract: Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: March 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Araz JAKALIAN, Michael John LAMBRECHT, Robin LAROUCHE-GAUTHIER, Malcolm HUESTIS, Man Un UNG, Xiaojing WANG, Arun YADAV, Jason Robert ZBIEG, Fabio BROCCATELLI